During immature capsid assembly in cells, the Gag protein of HIV-1 and other primate lentiviruses 25 co-opts a host RNA granule, forming a pathway of assembly intermediates that contains host components, 26 including two cellular enzymes shown to facilitate assembly, ABCE1 and DDX6. Here we asked whether 27 a non-primate lentivirus, feline immunodeficiency virus (FIV), also forms such RNA-granule-derived 28 intracellular capsid assembly intermediates. First, we found that, unlike for HIV-1, the FIV completed 29 immature capsid and the largest putative assembly intermediate are unstable during analysis. Next, we 30 identified in situ cross-linking conditions that overcame this problem and revealed the presence of FIV 31
Introduction
immature capsid we hypothesized that one or more of the putative FIV assembly intermediates might be 232 unstable. To test this hypothesis, feline G355-5 cells were transfected to express FIV CO-Gag and prior 233 to harvest were either mock treated or treated with DSP to cross-link putative FIV assembly 234
intermediates. Harvested lysates were subjected to velocity sedimentation, and analyzed by WB for FIV 235
Gag. The velocity sedimentation conditions used here are expected to optimally separate ~10S, ~80S, 236 ~500S complexes; under these conditions, peaks in the ~80S and ~150S regions co-migrate and the 237 ~500S and ~750S regions overlap. Intracellular steady-state Gag levels in cell lysates from mock treated 238
and DSP cross-linked cells were comparable ( Fig. 2A) . In mock treated cell lysates, FIV Gag was found 239 in complexes corresponding to the HIV-1 ~10S and ~80S assembly intermediates with only faint FIV 240
Gag bands observed in the ~500S region (Fig. 2B , upper panel). In contrast, the DSP cross-linked cell 241 lysates contained abundant FIV Gag in complexes corresponding to the HIV-1 ~10S, ~80S, and ~500S 242 assembly intermediates (Fig 2B, lower panel) . Taken together, these data suggest that FIV forms 243 immature capsid assembly intermediates that are similar in size to previously described HIV-1 assembly 244
intermediates, but with the larger ~500S FIV intermediate being less stable than its HIV-1 counterpart, as 245 is the case with the released FIV immature capsid. 246
To determine if putative FIV assembly intermediates could also be detected in cells transfected to 247 express an FIV proviral clone, we analyzed cross-linked G355-5 cells transfected to express FIV pro-, 248 using velocity sedimentation and WB of gradient fractions for FIV Gag (Fig 2C, upper 
panel). As with 249
FIV CO-Gag, the ~10S, ~80S, and ~500S putative FIV assembly intermediates were detected. In the case 250 of FIV pro-, the putative ~10S and ~80S intermediates and the ~500S completed immature capsids were 251 abundant in the cross-linked lysates, with more of the late ~500S putative assembly intermediate and less 252 of the completed ~750S capsid relative to FIV CO-Gag (Fig. 2B, lower panel) . The difference in the 253 amount of intracellular ~750S completed immature capsids present at steady state could be explained by 254 budding kinetics that may differ with constructs and cell types, as has been observed for HIV-1 (22, 25, 255 27). As a positive control, COS-1 cells transfected to express HIV-1 LAI pro-were also analyzed by 256 velocity sedimentation without prior cross-linking. WB of gradient fractions for HIV-1 Gag revealed the 257 ~10S, ~80S, and ~500S HIV-1 assembly intermediates, as expected (Fig. 2C, lower panel) . Moreover, 258
comparison of results for HIV-1 expressing lysates confirms that FIV Gag forms complexes that are 259 similar in size to previously defined HIV-1 assembly intermediates, with the late ~500S FIV complex 260 being less stable than the corresponding HIV-1 late assembly intermediate. Subsequent analyses of 261 intracellular FIV assembly intermediates were all performed following cross-linking in situ. 262
Previously, rigorous pulse-chase studies demonstrated that HIV-1 Gag complexes identified in cell 263 lysates are part of a pathway of sequentially formed assembly intermediates; moreover, HIV-1 Gag 264 mutants that are assembly-defective are arrested at different steps of the assembly pathway and 265 accumulate only those assembly intermediates that precede the point of arrest, further demonstrating the 266 sequential progression of Gag through the pathway (Fig 3A; (21, 22, 24, 25)). Thus, to further test the 267 hypothesis that the FIV Gag-containing complexes that we identified in cells (Fig. 2B) are assembly 268
intermediates, we generated five FIV Gag mutants that are predicted to be either budding-defective or 269 assembly-defective, and determined the pattern of FIV Gag complexes produced in cells transfected with 270 each of these mutants. If key assembly-defective FIV Gag mutants are arrested at the same complex as 271 the corresponding assembly-defective HIV-1 Gag mutant and forms only the FIV Gag-containing 272 complexes that precede the point of arrest, then FIV Gag complexes are likely part of a pathway of 273 sequential assembly intermediates analogous to the HIV-1 assembly pathway. 274
To generate a budding-defective mutant (FIV CO-Gag P438A/P441A), we altered the TSG101 275 binding motif in FIV p2 from PSAP to ASAA, which is known to reduce production of FIV VLPs (Fig.  276 3B; (11)). Given that the analogous PTAP mutation in HIV-1 inhibits virus budding but not Gag 277 multimerization (38, 39), we would expect FIV CO-Gag P438A/P441A to be assembly-competent and 278 therefore form all the assembly intermediates, but subsequently fail to complete budding and release. We 279 also generated two FIV Gag mutants that are expected to be assembly-defective. One is truncated at the 280 end of CA, resulting in expression of only MA-CA (FIV CO-Gag MACA; Fig. 3B ). We would expect 281 that, like HIV-1 MACA ( Fig. 3A;(22) ), FIV MA-CA would fail to produce VLPs, would be arrested as 282 the ~10S assembly intermediate, and would thereby mark the first step in the assembly pathway. 283
Moreover, a similar truncation mutant in FIV Gag, FIV MA-CA-p1, also does not produce VLPs (9). In 284 the second FIV Gag mutant, the glycine at position 2 of FIV Gag was substituted with an alanine to 285 generate FIV CO-Gag G2A (Fig. 3B) ; this mutation is known to reduce VLP production (8). The 286 analogous HIV-1 Gag G2A mutation fails to undergo myristoylation and subsequent targeting to the 287 plasma membrane (PM) site of assembly, and is arrested as a cytosolic ~80S assembly intermediate (Fig.  288   3B; (22) ). Hence, we expected FIV CO-Gag G2A to be arrested at the ~80S assembly intermediate. To 289 verify that these three constructs express in cells and display the expected phenotype in assembly or 290 budding, we examined steady-state intracellular Gag levels as well as VLP production (Fig. 3C) . The 291 budding mutant, FIV Gag P438A/P441A, was expressed at a level comparable to WT FIV CO-Gag and 292 displayed a three-fold reduction in VLP release relative to WT (Fig. 3C ). Although this budding defect 293
was not as profound as observed previously (11), this may reflect differences in cell lines (40). For the 294 two other FIV Gag mutations described thus far (G2A and MACA), almost no VLPs were released from 295 transfected cells, despite intracellular Gag levels similar to WT FIV Gag (Fig. 3C ), confirming that both 296 are assembly-defective. 297
Having established that these three FIV Gag mutants (P438A/P441A, G2A, and MACA) display the 298 expected VLP phenotypes, we expressed them in cells at similar steady-state levels ( Fig. 4A ) and asked 299 whether they are arrested in the assembly pathway in a manner similar to the comparable HIV-1 Gag 300 mutants ( Fig. 4B and 4C ). Velocity sedimentation analysis of cell lysates revealed that FIV CO-Gag 301 produces the expected pattern of putative intracellular assembly intermediates, displaying a prominent 302 ~80S complex and a less prominent ~500S complex as well as the ~750S completed immature capsid. As 303 expected, the budding-defective P438A/P441A mutant produced all the putative assembly intermediates 304 formed by FIV CO-Gag, consistent with immature capsid assembly being unaffected by mutation of the 305 TSG101 binding motif that is important for budding but not assembly. Interestingly, the budding-306 defective P438A/P441A mutant accumulated more ~750S completed immature capsids than WT FIV CO-307
Gag, consistent with the completed P438A/P441A immature capsids being arrested at the PM before 308 undergoing release. In contrast, FIV CO-Gag MACA only produced the ~10S complex, and FIV CO-Gag 309 FIV CO-Gag MACA mutant and assembly-defective FIV CO-Gag G2A mutant were each arrested at the 311 same Gag-containing complex as their HIV-1 counterparts ( Fig. 3A; (22) ). Taken together, these data 312 further support the model that intracellular FIV Gag assembles via a stepwise pathway of assembly 313
intermediates, analogous to those described previously for HIV-1, and that these assembly intermediates 314
can be identified at steady state in cell lysates. 315
Given the important role of the CA domain in HIV-1 immature capsid assembly, we also wanted to 316 identify point mutations in FIV CA that result in assembly defects and determine if they also cause arrest 317 of FIV Gag in the putative assembly pathway. While point mutations in CA-NTD and -CTD that impair 318 HIV-1 immature capsid assembly have been defined ((16, 24, 41-45)), they have not yet been identified 319 for FIV. Such FIV point mutants would allow a finer mapping FIV CA function and would allow us to 320 compare arrest of FIV and HIV assembly-defective mutants, thereby providing additional insights into 321 assembly mechanisms. Since high-resolution structures of the HIV-1 CA-NTD and CA-CTD are 322 available, we sought to identify FIV residues that correspond to known HIV-1 assembly-critical residues 323 by aligning the structure of the FIV CA subdomains onto the structure of the HIV-1 CA subdomains (Fig.  324 5A). For CA-CTD, we aligned the published FIV CA-CTD structure (PDB accession number 5DCK; 325 (18)) with the HIV-1 CA-CTD domains from a published structure of HIV-1 CA (PDB accession number 326 5L93; (46)). However, because a high-resolution structure of FIV CA-NTD has not been reported, we 327 generated a model of the FIV CA-NTD structure, using SWISS-MODEL, with the published RELIK CA-328 NTD structure as a template (PDB accession number 2XGU; (19)). This FIV CA-NTD model was then 329 aligned with the published HIV-1 CA-NTD structure (PDB accession number 5L93; (46); Fig. 5A ). 330
After aligning the FIV CA subdomain structures on an HIV-1 CA structure (Fig. 5A ), we next asked 331 which residues in the FIV structures most closely correspond to assembly-critical HIV CA residues. In 332 CA-NTD, residues in helix 4 were of particular interest because helix 4 forms an exposed surface ((44)) 333
and is critical for inter-hexameric CA-NTD contacts in a high-resolution cryoEM structure ((46); Fig.  334 5B). In keeping with this, the HIV-1 Gag helix 4 mutant E207A/E208A (Fig. 5C ) displays reduced VLP 335 production (44) but forms all the assembly intermediates, including the late ~500S assembly intermediate 336 (22), indicating arrest just prior to formation of the ~750S completed capsid (Fig. 3A) . Moreover, a 337 recent cryoEM structure of HIV-1 capsid suggests that E207 and E208 in CA-NTD helix 4 may 338 participate in a salt bridge with R150 in CA-NTD helix 1 of a neighboring 3-fold symmetry mate ((46); 339 Fig. 5D ). This interaction may contribute to stabilizing the immature HIV-1 capsid; thus, it is possible 340 that the observed arrest of the E207/E208 mutant in the assembly pathway is explained by disruption of 341 this salt bridge. CA-NTD helix 4 is also important for FIV immature capsid assembly since its deletion 342 reduces VLP production (9). Thus, we chose to mutate the FIV residues Q209/L210 to alanine based on 343 their alignment with E207/E208 in the superimposed HIV-1 and FIV CA-NTDs structure ( Fig. 5A and 344 C). Additionally, the side chains of Q209/L210 residues had a similar orientation relative to the 345 corresponding E207/E208 residues in the HIV-1 CA structure (Fig. 5A) , further supporting the selection 346 of Q209/L210 for mutation. Consistent with their similar alignment and orientation, QL (or QM) residues 347 are highly conserved at this position in FIV variants from domestic cats (present in 312 out of 322 FIV 348
Gag domestic cat sequences deposited to NCBI; Fig. 5D and Suppl. Table 1 ). Notably, as described in 349 the Discussion section, the finding that Q209 in FIV CA-NTD of domestic cats corresponds to E209 in 350 HIV-1 CA-NTD based on alignment and orientation raises some interesting structural issues, since unlike 351 glutamic acid, glutamine would not be expected to form a salt bridge in FIV Gag due to its lack of a 352 negative charge. 353
To test whether the FIV Q209/L210 residues are analogous to the assembly-critical HIV-1 E207/E208 354 residues, we introduced Q209A/L210A mutation into FIV CO-Gag and examined the effect on VLP 355 production and progression through the assembly pathway. We found that VLP production by FIV CO-356 Gag Q209A/L210A was dramatically reduced despite intracellular Gag expression (Fig. 3C) , thus 357 recapitulating the VLP defect observed for the corresponding HIV-1 mutant (22, 44). When expressed in 358 cells at similar intracellular levels as WT FIV CO-Gag (Fig. 6A) , FIV CO-Gag Q209A/L210A formed the 359 ~10S, ~80S, and ~500S complexes, but little to no ~750S completed immature capsid, as indicated by 360 velocity sedimentation analysis ( Fig. 6B and C) . From these data, we conclude that FIV CO-Gag 361 Q209A/L210A is arrested at the ~500S assembly intermediate, since it forms the ~500S intermediate 362 (Fig. 6C ) but fails to complete assembly and release (Fig. 3C) , as observed for the corresponding HIV-1 363 E207A/E208A mutant ( Fig. 3A; (22) ). 364
Similarly, we also sought to identify residues in FIV CA-CTD that correspond to assembly-critical 365 HIV-1 residues. In HIV-1 CA-CTD, CA helix 9 mediates an important inter-hexameric CA-CTD 366 dimerization interface in the completed immature capsid ((16); Fig. 5B ). We would expect that FIV helix 367 9 also forms this critical CA-CTD dimer interface, especially given that FIV CA-CTD can functionally 368 replace SIV CA-CTD, as shown with SIV-FIV chimeras (47). It was demonstrated previously that the 369 W316/M317 mutation within helix 9 of HIV-1 CA inhibits VLP production (22, 44) and arrests HIV-1 370
Gag assembly at the ~80S intermediate ( Fig 3A; (22) ). To determine if FIV assembly also depends on 371 this critical CA-CTD dimerization interface, FIV Gag residues Y311 and L312 were chosen for mutation 372
based on their alignment with, and similar orientation to, residues W316 and M317 in HIV-1 helix 9 (Fig.  373 
5A and C). 374
When expressed in cells, FIV CO-Gag Y311A/L312A displayed dramatically reduced VLP 375 production ( Fig. 3C) , thus recapitulating the VLP defect observed for the analogous HIV-1 Gag 376 W316/M317 (22, 44). Velocity sedimentation analysis revealed that FIV CO-Gag Y311A/L312A 377 produced only the ~10S and ~80S complexes, while WT CO-Gag produced 10S, ~80S, and ~500S/750S 378 intermediates when expressed at similar steady-state intracellular levels and analyzed in parallel (Fig. 6A-379 C). Thus, FIV CO-Gag Y311A/L312A is arrested at the ~80S putative assembly intermediate as 380
observed for the corresponding HIV-1 W316A/M317A mutation ( Fig. 3A; (22) ). Together, analysis by 381 velocity sedimentation shows that each of the four assembly-defective Gag mutants that we examined is 382 arrested at the same assembly intermediate as its HIV-1 counterpart (Figs. 4 and 6; summarized in Fig.  383 
7A). 384
To further confirm that the FIV Gag-containing complexes are assembly intermediates, we asked if 385 they contain the same cellular proteins found in HIV-1 assembly intermediates. The ~80S and ~500S 386 HIV-1 capsid assembly intermediates contain several host proteins, of which the best studied are the 387 enzymes ABCE1 (26) and DDX6 (27). Both ABCE1 and DDX6 facilitate events in HIV-1 assembly (26, 388 27) and serve as markers for assembly intermediates. Thus, we asked whether FIV Gag is also associated 389 with endogenous ABCE1 and DDX6 in feline G355-5 cells. FIV CO-Gag was expressed in G355-5 cells 390 and cell lysates were subjected to immunoprecipitation with either antibody to human ABCE1 or 391 antibody to human DDX6 alongside a non-immune control, followed by WB with an antibody to FIV 392 CA-CTD to detect co-immunoprecipitated FIV Gag. Because both ABCE1 and DDX6 are highly 393 conserved between humans and domestic cat (99.8% identity) and the ABCE1 and DDX6 antibodies we 394 used (described previously (26, 27)) are directed against peptides with 100% identity between humans 395 and domestic cat, we expected both antibodies to recognize the feline homologs. Indeed, we found that 396
WT FIV Gag was associated with endogenous feline ABCE1 and DDX6 by immunoprecipitation (Fig.  397 7B). Thus, like HIV-1 Gag, FIV Gag appears to co-opt an ABCE1-and DDX6-containing RNA granule. 398
The ~10S HIV-1 assembly intermediate, which corresponds to soluble Gag, is not associated with 399 ABCE1 and DDX6 (26, 27, 31), indicating that HIV-1 Gag likely associates with ABCE1 and DDX6 400 after it targets to an RNA granule. Given this, we would not expect the assembly-incompetent FIV 401 MACA, which is arrested at the ~10S assembly intermediate ( Gag forms complexes in cells that resemble well-studied HIV-1 immature capsid assembly intermediates 470 in size and shape (Fig. 2) ; second, assembly-defective FIV Gag mutants are arrested in the putative 471 assembly pathway and the points of arrest are the same as for the analogous HIV-1 Gag assembly-472 defective mutants (Fig. 4 and 6) ; third, FIV Gag is associated with the RNA granule proteins ABCE1 and 473 DDX6 by co-immunoprecipitation ( Fig. 7B ), as observed for HIV-1 Gag in assembly intermediates; and 474 fourth, assembling FIV Gag colocalizes with ABCE1 in situ, while an assembly-defective mutant does 475 not ( Fig. 8 ). Taken together these data argue that the ~80S and ~500S FIV Gag-containing complexes 476 correspond to early and late immature capsid assembly intermediates, respectively, and that the immature 477 assembly pathway defined by studies of HIV-1 is conserved between primate and non-primate 478 lentiviruses (Fig. 7A) . Below we will use the term assemblysome to refer to collectively RNA-granule 479 derived capsid assembly intermediates of different sizes (e.g. the ~80S and ~500S HIV-1 and FIV 480 assembly intermediates). 481
Our finding that both primate (HIV-1, HIV-2, SIV) and non-primate (FIV) lentiviruses appear to form 482 assemblysomes by co-opting the same subclass of ABCE1-and DDX6-containing RNA granules 483
suggests that many or all Gag proteins have evolved to utilize this cellular complex. While many 484 questions about these RNA granules remain unanswered, this conservation argues that these granules play 485 an important role in the retroviral lifecycle. Other types of RNA granules, such as P bodies and stress 486 granules, transiently store non-translating cellular mRNA (reviewed in (49)); thus, it is possible that these 487 ABCE1-and DDX6-containing complexes could also be sites for storing non-translating cellular mRNA. 488
Moreover, because FIV and HIV-1 unspliced RNA resembles cellular mRNA in that it is both capped and 489 polyadenylated, one might expect unspliced FIV and HIV-1 viral RNA to also be stored in these ABCE1-490 and DDX6-containg granules. Consistent with this possibility, unspliced HIV-1 RNA is associated with 491 20 ABCE1 in these RNA granules (22). Thus, targeting of retroviral Gag proteins to this RNA granule could 492 be advantageous for a number of reasons. First, assembling Gag could take advantage of cellular 493 facilitators of immature capsid assembly present in RNA granules, such as ABCE1 and DDX6 with HIV-494 1 (22, 25-27). Second, these RNA granules could provide a site in which Gag becomes concentrated, 495 thereby facilitating Gag-Gag interactions. Third, RNA granule localization could bring assembling Gag 496 into proximity with granule-associated unspliced retroviral RNA to facilitate packaging of the RNA 497 genome into the assembling virus. Finally, these RNA granules may also shield retroviral RNA or other 498 retroviral components from host innate immune sensing. 499
Many viruses are known to utilize RNA granules at various stages of their lifecycles (50). Canonical 500 RNA granules include stress granules and P bodies, both of which are much larger than the ABCE1-and 501 DDX6-containing RNA granule from which assembly intermediates are derived. For example, P bodies 502 range from 100 -300 nm in size (51) whereas our ~80S assembly intermediate should be approximately 503 the same size as a ribosome (~25 nm, (52)). Others have reported that HIV-1 Gag is associated with 504 RNA granule proteins including Staufen1 (53, 54), AGO2 (55), and MOV10 (56). However, HIV-1 Gag 505
is not found in stress granules (54), whose formation is induced by stress; nevertheless, Gag has been 506 shown to modulate formation of stress granules (54, 57, 58). Similarly, a recent study reported that HIV-507 1 Gag does not co-localize with P bodies by fluorescent microscopy (59). Consistent with that report 508 (59), our recent PLA studies show that HIV-1 Gag is not typically associated with P bodies although it is 509 associated with the P body protein DDX6 in much smaller granular structures (Barajas B and Lingappa 510 JR, unpublished observations). Thus, P bodies, stress granules, and assemblysomes clearly represent 511 RNA granules of different sizes and functions; however, more work will be needed to understand how 512 they are related to each other and to the HIV-1 lifecycle. One hypothesis consistent with published data is 513 that the ABCE1-and DDX6-containing granules that are co-opted by Gag are subunits of P bodies and/or 514 stress granules that can also exist independent of P bodies and stress granules. In support of this 515 hypothesis, the ABCE1-and DDX6-containing granules that are co-opted by Gag share at least two 516 components with P bodies (DDX6 and AGO2 (27)), and DDX6 is also found in stress granules (reviewed 517 21 in (60)). Thus, this subunit hypothesis would explain why Gag is associated with DDX6 and ABCE1 but 518 does not co-localize with P bodies or stress granules, and why P bodies and stress granules can be 519 impacted when Gag is expressed. While future studies will be needed to test these possibilities, the 520 current study adds to a large body of evidence indicating that a common feature of Gag proteins is their 521 ability to co-opt a unique ABCE1-and DDX6-containing RNA granule during immature capsid 522
assembly. 523
The association of HIV-1 Gag with DDX6 and ABCE1 in assemblysomes was shown previously 524 using co-immunoprecipitation and immunoelectron microscopy (21, 27). Here we showed that, like HIV-525 1 Gag, FIV Gag is associated with both of these host enzymes by co-immunoprecipitation. Here for the 526 first time, we utilized a PLA assay that allowed us to demonstrate co-localization of FIV Gag with 527 ABCE1 in situ using fluorescent microscopy. Unlike direct or indirect fluorescent microscopy, PLA 528 results in fluorescent spots only when two proteins are in close proximity, thus allowing co-localization to 529 be quantified even when proteins are present diffusely throughout the cytoplasm. Thus, taken together 530 two different in situ approaches -PLA and immunoelectron microscopy -support the finding that 531 assembling Gag proteins of various lentiviruses form ABCE1-containing assemblysomes, while 532 assembly-incompetent MACA Gag mutants do not. Moreover, our PLA results suggest that PLA may be 533 a promising approach for in situ confirmation of other retroviral-host protein associations. 534
Although our study found numerous similarities between FIV and HIV-1, we did find one significant 535 difference, namely that the late ~500S FIV assembly intermediate and completed FIV immature capsids 536 were relatively unstable compared to the corresponding HIV-1 complexes. Notably, our study 537 demonstrated that in situ cross-linking overcomes the inherent lability of FIV complexes, allowing these 538 complexes to be stabilized and analyzed. Thus, the cross-linking approach that we developed and 539 validated here should allow assemblysomes for these and other retroviral capsids to be isolated and 540 analyzed intact in the future. 541
The current study also advances our understanding of residues and interfaces critical for assembly of 542 FIV immature capsids, and may have identified an example of co-evolution that could have structural 543 implications. Previously, it has been shown that E207/E208 in helix 4 of HIV-1 CA-NTD is required for 544 assembly (44) and for progression past the ~500S step in the assembly pathway (22), consistent with a 545 study showing that these residues are critical for an inter-hexameric interface formed between helix 4 and 546 helix 1 of a neighboring 3-fold symmetry mate (46). Here we showed that Q209/L210 in FIV CA-NTD 547 helix 4 function in a manner analogous to E207/208 in helix 4 of HIV-1 CA-NTD, in that Q209/L210 are 548 important for VLP production and for progression past the ~500S Gag-containing complex (Fig 6B and  549 C). However, we also noted a difference in the HIV-1 and FIV residues that refines our understanding of 550 this interface. Others have proposed that a salt bridge may form between the negatively charged E207 551 and E208 in helix 4 of HIV-1 CA-NTD and the positively charged R150 in helix 1 of HIV-1 Gag CA-552
NTD (E-R salt bridge; (46)); but this salt bridge is unlikely to form between the comparable FIV Gag 553 residues, Q209/L210 (neither of which is negatively charged), and K152, which is analogous to HIV-1 554 R150. Our finding that FIV Gag Q209/L210 is required for progression past the ~500S putative assembly 555 intermediate and may serve a similar function as E207/E208 raises the possibility that a Q209-K152 556 hydrogen bond (Q-K hydrogen bond) in the FIV immature capsid structure could substitute for the 557 proposed E-R salt bridge in the HIV-1 immature capsid structure and be sufficient for formation of this 558 critical inter-hexameric helix1-helix4 CA-NTD interface. If this is the case, then the FIV Q-K hydrogen 559 bond in place of the E-R salt bridge at the inter-hexameric CA-NTD interface could contribute to the 560 marked instability of completed FIV immature capsids and the late (but not the early) FIV assembly 561 intermediates relative to their HIV-1 counterparts, as shown above (Fig. 1D and 2B) . While Q209 and 562 K152 are well conserved in FIV Gag sequences from isolates obtained from domestic cats (Felis catus; 563 Fig. 5D ), they are not present in FIV isolates from other felines besides domestic cats with isolates from 564 lions, cougars, bobcats, and Pallas' cats (Panthera leo, Puma concolor, Lynx rufus, and Otocolobus 565 manul, respectively), which more closely resemble HIV-1 at the relevant positions (Fig. 5D ). This 566 observation raises the possibility that the E-R salt bridge could form in FIV Gag isolates from lion, 567 cougar, bobcat, or Pallas' cat and that the immature FIV capsids formed by those isolates may be more 568 stable than those from isolates found in domestic cats. Additionally, this might be an example of co-569 evolved substitutions (18), since helix 1 contains an arginine when helix 4 contains a glutamic acid (e.g. 570 in HIV-1 and FIV isolates from species besides domestic cat), while helix 1 contains a lysine when helix 571 4 contains a glutamine (e.g. in most FIV isolates from domestic cats). Notably, arginine forms bonds in 572 more directions and is therefore thought to be more stabilizing than lysine (61), thus providing another 573
reason, in addition to the salt bridge, for why the E-R pair may be more stabilizing than the Q-K pair. 574
Future mutational studies could address whether the instability of FIV immature capsid and the ~500S 575 assembly intermediate results from having a Q-K pair in place of the E-R pair at the inter-hexameric CA-576
NTD interface. 577
Another important HIV-1 interface is the CA-CTD dimer interface, formed by residues W316/M317 578 in helix 9 of HIV CA (16, 46). Our finding that mutation of the corresponding two hydrophobic residues 579 (Y311/L312) in FIV CA helix 9 inhibited VLP production and arrested the assembly pathway at the same 580 assembly intermediate as observed with the HIV-1 CA-CTD dimer interface mutant, argue that helix 9 in 581 CA-CTD plays a similar role in FIV and HIV-1 immature capsid assembly, and likely forms the dimer 582 interface in both cases. Although a previous study found that deletion of FIV CA helix 9 and part of helix 583 10 did not inhibit VLP production (9), deletions and point mutations can have very different phenotypes 584 and are not always comparable. 585
Finally, a key implication of our findings is that compounds that target the ABCE1-and DDX6-586 containing RNA granules co-opted by these lentiviral Gag proteins could have broad acting antiretroviral 587 activity, inhibiting both primate and non-primate lentiviruses and possibly other retroviruses. Notably, 588 small molecules that target ABCE1-containing complexes are known to effectively inhibit rabies virus 589 assembly in vitro, thereby providing proof-of-principle that ABCE1-containing assemblysomes are 590 druggable (32). The finding that rabies virus, HIV-1 and other primate lentiviruses, and the non-primate 591 lentivirus FIV, all form ABCE1-containing assemblysomes also suggests a much broader conservation of 592 this mechanism of assembly. 593 594 595
Materials and Methods 596
Construction of proviral and codon-optimized FIV Gag plasmids. The proviral clone FIV 34TF10A 597 was obtained from the NIH AIDS Reagent program (NIH AIDs Reagent Program, catalog #1236). The 598 previously described orfA premature stop codon (TGA) in this proviral clone (34) was reverted to 599 tryptophan (TGG) by overlap extension PCR. This construct was used to generate FIV, in which the FIV 600 promoter is replaced with CMV promoter, using a previously described strategy (36). To make FIV pro-, 601 a non-overlapping site-directed mutagenesis approach was used to introduce the D30N mutation into the 602 HIV-1 EE QL or QM EL EL 
